0000899243-22-034368.txt : 20221027 0000899243-22-034368.hdr.sgml : 20221027 20221027212303 ACCESSION NUMBER: 0000899243-22-034368 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220913 FILED AS OF DATE: 20221027 DATE AS OF CHANGE: 20221027 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolph Timothy CENTRAL INDEX KEY: 0001779479 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 221338815 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS, INC. STREET 2: 170 HARBOR WAY, 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2022-09-13 2022-09-15 0 0001744659 Akero Therapeutics, Inc. AKRO 0001779479 Rolph Timothy C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Scientific Officer Common Stock 2022-09-13 4 M 0 10000 6.36 A 256337 D Common Stock 2022-09-13 4 S 0 22500 29.18 D 233837 D Stock Option (Right to Buy) 6.36 2022-09-13 4 M 0 10000 0.00 D 2029-01-15 Common Stock 10000 62756 D On September 15, 2022, the reporting person filed a Form 4 which inadvertently omitted the exercise of 10,000 options by the reporting person. The shares of Common Stock underlying those options were subsequently sold pursuant to a Rule 10b5-1 trading plan as reported in the original Form 4. This amendment to the original Form 4 is being filed solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019. /s/ Jonathan Young, Attorney-in-Fact 2022-10-27